Insider · CIK 0001869200
Mary L. Rotunno
Files at VTGN (Vistagen Therapeutics, Inc.). First filing -, latest -.
In brief
Mary L. Rotunno files SEC Form 4 as director at VTGN (Vistagen Therapeutics, Inc.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Mary L. Rotunno has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 1 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 9, 2025 | VTGN Vistagen Therapeutics, Inc. | AGrant or award Non-Qualified Stock Option (right to buy)derivative | +17,600 | $0.00 | $0 | 17,600 | Sep 11, 2025 |
Questions about Mary L. Rotunno
Answered from the filings on this page, as of the latest one.
Is Mary L. Rotunno buying or selling?
Mary L. Rotunno has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Mary L. Rotunno's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Mary L. Rotunno has 0.
Where does Mary L. Rotunno file Form 4?
Mary L. Rotunno has filed Form 4 at VTGN (Vistagen Therapeutics, Inc.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.